ReviewJournal of the American College of Cardiology2020
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.
10 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph
Review in Journal of the American College of Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 10 registered trials, which are not on this map. Cited by 1,730 papers, 10 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,730citing papers in PubMed, 10 pooled it
345.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome
Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients
Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19
Effectiveness of Thromboprophylaxis With Low Molecular Weight Heparin in Critically Ill Patients With COVID-19. A Prospective, Cohort, Multicenter Study.
CMR Findings in COVID-19 Patients Presenting With Myocardial Infarction
Study of Coagulation Profile and Role of Heparin-like Effect in Patients With COVID-19
Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)
COVID 19 A Prospective Case Control Pathophysiological Study of Long Term Implications
Intensive Dose Tinzaparin in Hospitalized COVID19 Patients
Who cites it
1,730 citing papers in PubMed, 10 syntheses or guidelines pooled it, 2,917 citations in OpenAlex.
- Associated thromboembolic events to the post COVID syndrome: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Pooled it
- Worldwide impact of COVID-19 on hospital admissions for non-ST-elevation acute coronary syndromes (NSTACS): a systematic review with meta-analysis of 553 038 cases.European heart journal. Quality of care & clinical outcomes · 2024Pooled it
- Prophylactic-dose direct oral anticoagulants for non-hospitalised people with COVID-19: A meta-analysis of randomised controlled trials.Journal of global health · 2024Pooled it
- Effect of anticoagulation on the incidence of venous thromboembolism, major bleeding, and mortality among hospitalized COVID-19 patients: an updated meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Effect of antiplatelet therapy after COVID-19 diagnosis: A systematic review with meta-analysis and trial sequential analysis.PloS one · 2024Pooled it
- Prophylactic anticoagulants for non-hospitalised people with COVID-19.The Cochrane database of systematic reviews · 2023Pooled it
- Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception: a Cochrane systematic review.BMJ sexual & reproductive health · 2023Pooled it
- SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.Arquivos brasileiros de cardiologia · 2023Guideline
- Pooled it
- Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.Circulation · 2023Trial
- Plasma proteomics reveal SERPINA1 and CD59 as candidate biomarkers for COVID-19 severity stratification and prognosis prediction.Annals of medicine · 2026Article
- Global burden of venous thromboembolism: incidence and outcome estimates of deep-vein thrombosis and pulmonary embolism.Nature reviews. Cardiology · 2026Review
- Microscopic vessel caliber patterns in pulmonary thromboembolism: Clinical and autopsy correlations in a 10-year autopsy series.Forensic science, medicine, and pathology · 2026Article
- Fibrin-Binding Peptide-Functionalized HBiomedicines · 2026Article
- Microscopic giant platelets versus automated mean platelet volume for severity assessment in COVID-19.Medicine · 2026Article
- Arterial and venous thromboembolism in hospitalized patients with COVID-19: a national multicenter cohort study.Blood vessels, thrombosis & hemostasis · 2026Article
- Six Years of COVID-19: Lessons from Epidemiology, Vaccination Campaigns, Clinical Risk Stratification, and Thromboembolic Surveillance.Vaccines · 2026Review
- Article
- Tissue-specific autoantibody signatures reveal immune alterations undetected by routine serology in long COVID.GeroScience · 2026Article
1,670 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
47 authors at 20 institutions in 13 countries.
Behnood BikdeliNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York; Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York. Electronic address: bb2813@cumc.columbia.edu.
Mahesh V MadhavanNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York. Electronic address: mvm2122@cumc.columbia.edu.
David JimenezRespiratory Department, Hospital Ramón y Cajal and Medicine Department, Universidad de Alcalá (Instituto de Ramón y Cajal de Investigación Sanitaria), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain.
Taylor ChuichNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York.
Isaac DreyfusNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York.
Elissa DrigginNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York.
Caroline Der NigoghossianNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York.
Walter AgenoDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
Mohammad MadjidMcGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas.
Yutao GuoDepartment of Cardiology, Chinese PLA General Hospital, Beijing, China.
Liang V TangInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yu HuInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jay GiriCardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.
Mary CushmanUniversity of Vermont Medical Center, Burlington, Vermont.
Isabelle QuéréDepartment of Vascular Medicine, University of Montpellier, Centre Hospitalier Universitaire Montpellier, InnoVTE F-CRIN Network, Montpellier, France.
Evangelos P DimakakosOncology Unit GPP, Sotiria General Hospital Athens School of Medicine, Athens, Greece.
C Michael GibsonHarvard Medical School, Boston, Massachusetts; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Giuseppe LippiLaboratory of Clinical Chemistry and Hematology, University Hospital of Verona, Verona, Italy.
Emmanuel J FavaloroHaematology Laboratory, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia; Sydney Centres for Thrombosis and Haemostasis, Westmead, New South Wales, Australia.
Jawed FareedLoyola University Medical Center, Chicago, Illinois.
Joseph A CapriniPritzker School of Medicine, University of Chicago, Chicago, Illinois.
Alfonso J TafurPritzker School of Medicine, University of Chicago, Chicago, Illinois; Division of Vascular Medicine, Department of Medicine, NorthShore University HealthSystem, Skokie, Illinois.
John R BurtonNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York.
Dominic P FranceseClinical Trials Center, Cardiovascular Research Foundation, New York, New York.
Elizabeth Y WangNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York.
Anna FalangaDepartment of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, University of Milan Bicocca, Bergamo, Italy.
Claire McLintockAuckland City Hospital, Auckland, New Zealand.
Beverley J HuntSt Thomas' Hospital, London, United Kingdom.
Alex C SpyropoulosDonald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, New York.
Geoffrey D BarnesCenter for Bioethics and Social Science in Medicine, University of Michigan, Ann Arbor, Michigan; Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan.
John W EikelboomPopulation Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Ido WeinbergHarvard Medical School, Boston, Massachusetts; Massachusetts General Hospital, Boston, Massachusetts.
Sam SchulmanDepartment of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; McMaster University, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
Marc CarrierOttawa Hospital Research Institute, Ottawa, Ontario, Canada.
Gregory PiazzaHarvard Medical School, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
Joshua A BeckmanVanderbilt University School of Medicine, Nashville, Tennessee.
P Gabriel StegINSERM U1148, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, FACT (French Alliance for Cardiovascular Trials), Paris, France; Université Paris, Paris, France; Royal Brompton Hospital, Imperial College London, London, United Kingdom.
Gregg W StoneClinical Trials Center, Cardiovascular Research Foundation, New York, New York; Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Stephan RosenkranzCologne Cardiovascular Research Center, Heart Center, Department of Cardiology, University of Cologne, Cologne, Germany.
Samuel Z GoldhaberHarvard Medical School, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts.
Sahil A ParikhNewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.
Manuel MonrealDepartment of Internal Medicine, Hospital Universitari Germans Trials i Pujol, Universidad Católica San Antonio de Murcia, Barcelona, Spain.
Harlan M KrumholzCenter for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut; Department of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Stavros V KonstantinidesCenter for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany.
Jeffrey I WeitzMcMaster University, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
Gregory Y H LipLiverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom; Aalborg University, Aalborg, Denmark.
Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function
NewYork–Presbyterian Hospital · USUniversity of Verona · ITBrigham and Women's Hospital · USUnion Hospital · CNUniversity of Cologne · DEWestmead Hospital · AUAuckland City Hospital · NZBeth Israel Deaconess Medical Center · USCardiovascular Institute of the South · USCardiovascular Research Foundation · USChinese PLA General Hospital · CNHarvard University · USHofstra University · USHospital of the University of Pennsylvania · USInserm · FRJohannes Gutenberg University Mainz · DELoyola University Medical Center · USNorthShore University HealthSystem · USOttawa Hospital · CASechenov University · RU
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MPOSTDOCTORAL TRAINING IN CARDIOVASCULAR DISEASET32HL007854 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Marwah Abdalla, Michael Argenziano · 1996 to 2026
$14.7MNCATS NIH HHS UL1 TR001863NHLBI NIH HHS T32 HL007854
Abstract
Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.
Indexed as
Coronavirus InfectionsPandemicsPneumonia, ViralThromboembolismAnticoagulantsBetacoronavirusCOVID-19Fibrinolytic AgentsHumansPlatelet Aggregation InhibitorsSARS-CoV-2Treatment OutcomeAnticoagulantsFibrinolytic AgentsPlatelet Aggregation Inhibitorsanticoagulantantiplateletantithrombotic therapyCOVID-19SARS-CoV-2thrombosis
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
NCT04420312ClinicalTrials.gov
NCT04445623ClinicalTrials.gov
NCT04466670ClinicalTrials.gov
NCT04505774ClinicalTrials.gov
NCT04623177ClinicalTrials.gov
NCT04628104ClinicalTrials.gov
and 4 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.